Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Children's Hospital Medical Center, Cincinnati
Participants who meet study eligibility will receive or continue to receive blinatumomab by continuous IV infusion for 28 days and also receive pembrolizumab (by IV infusion over 30 minutes) on day 12 of cycle 1 and day 5 of cycle 2.
One cycle lasts 35 days and patients will receive 2 cycles of therapy.
Age
1–40
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 1-40
Diagnosis of CD19 positive B-cell acute lymphoblastic leukemia (ALL) positive B-cell acute lymphoblastic leukemia (ALL) or CD19 positive B-cell lymphoma
Patients with CD19 positive B-ALL must have greater than or equal to 5% lymphoblast in the bone marrow AND meet one of the following criteria:
2nd or greater relapse
Any relapse after allo-HSCT
Refractory disease
Patients with CD19 positive relapsed/refractory lymphoma must be in 2nd or greater relapse or have refractory disease with the markers of disease burden
Karnofsky performance level greater than or equal to 50 % for patients older than 16
Lansky performance level greater than or equal to 50 % less than or equal to 16
Patients recovered from acute toxicities from prior anti-cancer chemotherapy including HSCT, cytotoxic therapy, prior blinatumomab, biologic, immunotherapy, monoclonal antibody, XRT and corticosteroid therapy
Patients with adequate hematological, renal, liver, cardiac, pulmonary and CNS organ functions
Female participants of child bearing age must have negative pregnancy test, abstain or use contraception for 120 days after last dose of pembrolizumab
You may not be if
Patients with the following diagnoses: CNS 3 leukemia, CNS lymphoma, active GVHD, Downs Syndrome, CNS or testicular relapse, optic nerve or retinal involvement requiring radiation therapy
Concurrent illnesses including: history of any grade autoimmune disorder, Grade 2 or higher hypothyroidism die to autoimmunity, uncontrolled infection, interstitial lung disease or pneumonitis
Patients with other concurrent malignancies
Patients who have received live vaccines within the last 30 days
Patients with history of solid organ transplant
Clareo Health | Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
